241 related articles for article (PubMed ID: 27167194)
1. Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress.
Zhang Y; Lai J; Du Z; Gao J; Yang S; Gorityala S; Xiong X; Deng O; Ma Z; Yan C; Susana G; Xu Y; Zhang J
Oncotarget; 2016 Jun; 7(23):34688-702. PubMed ID: 27167194
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.
Morgan MA; Parsels LA; Zhao L; Parsels JD; Davis MA; Hassan MC; Arumugarajah S; Hylander-Gans L; Morosini D; Simeone DM; Canman CE; Normolle DP; Zabludoff SD; Maybaum J; Lawrence TS
Cancer Res; 2010 Jun; 70(12):4972-81. PubMed ID: 20501833
[TBL] [Abstract][Full Text] [Related]
3. A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types.
Dinkelborg PH; Wang M; Gheorghiu L; Gurski JM; Hong TS; Benes CH; Juric D; Jimenez RB; Borgmann K; Willers H
Breast Cancer Res Treat; 2019 Apr; 174(3):605-613. PubMed ID: 30607635
[TBL] [Abstract][Full Text] [Related]
4. Radiosensitization of NSCLC cells to X-rays and carbon ions by the CHK1/CHK2 inhibitor AZD7762, Honokiol and Tunicamycin.
Liu B; Chen W; Li H; Li F; Jin X; Li Q
Radiat Environ Biophys; 2020 Nov; 59(4):723-732. PubMed ID: 32857208
[TBL] [Abstract][Full Text] [Related]
5. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.
Hauge S; Naucke C; Hasvold G; Joel M; Rødland GE; Juzenas P; Stokke T; Syljuåsen RG
Oncotarget; 2017 Feb; 8(7):10966-10979. PubMed ID: 28030798
[TBL] [Abstract][Full Text] [Related]
6. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.
Vance S; Liu E; Zhao L; Parsels JD; Parsels LA; Brown JL; Maybaum J; Lawrence TS; Morgan MA
Cell Cycle; 2011 Dec; 10(24):4321-9. PubMed ID: 22134241
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
Massey AJ
Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
[TBL] [Abstract][Full Text] [Related]
8. The Chk1 inhibitor AZD7762 sensitises p53 mutant breast cancer cells to radiation in vitro and in vivo.
Ma Z; Yao G; Zhou B; Fan Y; Gao S; Feng X
Mol Med Rep; 2012 Oct; 6(4):897-903. PubMed ID: 22825736
[TBL] [Abstract][Full Text] [Related]
9. Multiple DNA damage-dependent and DNA damage-independent stress responses define the outcome of ATR/Chk1 targeting in medulloblastoma cells.
Krüger K; Geist K; Stuhldreier F; Schumacher L; Blümel L; Remke M; Wesselborg S; Stork B; Klöcker N; Bormann S; Roos WP; Honnen S; Fritz G
Cancer Lett; 2018 Aug; 430():34-46. PubMed ID: 29753759
[TBL] [Abstract][Full Text] [Related]
10. ATR inhibition preferentially targets homologous recombination-deficient tumor cells.
Krajewska M; Fehrmann RS; Schoonen PM; Labib S; de Vries EG; Franke L; van Vugt MA
Oncogene; 2015 Jun; 34(26):3474-81. PubMed ID: 25174396
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint kinase‑1 inhibition and etoposide exhibit a strong synergistic anticancer effect on chronic myeloid leukemia cell line K562 by impairing homologous recombination DNA damage repair.
Fan Z; Luo H; Zhou J; Wang F; Zhang W; Wang J; Li S; Lai Q; Xu Y; Wang G; Liang A; Xu J
Oncol Rep; 2020 Nov; 44(5):2152-2164. PubMed ID: 32901871
[TBL] [Abstract][Full Text] [Related]
12. The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells.
Wang FZ; Fei HR; Cui YJ; Sun YK; Li ZM; Wang XY; Yang XY; Zhang JG; Sun BL
Apoptosis; 2014 Sep; 19(9):1389-98. PubMed ID: 24928205
[TBL] [Abstract][Full Text] [Related]
13. ATR/CHK1 inhibitors and cancer therapy.
Qiu Z; Oleinick NL; Zhang J
Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
[TBL] [Abstract][Full Text] [Related]
14. CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy.
Barker HE; Patel R; McLaughlin M; Schick U; Zaidi S; Nutting CM; Newbold KL; Bhide S; Harrington KJ
Mol Cancer Ther; 2016 Sep; 15(9):2042-54. PubMed ID: 27422809
[TBL] [Abstract][Full Text] [Related]
15. Prevention of DNA Replication Stress by CHK1 Leads to Chemoresistance Despite a DNA Repair Defect in Homologous Recombination in Breast Cancer.
Meyer F; Becker S; Classen S; Parplys AC; Mansour WY; Riepen B; Timm S; Ruebe C; Jasin M; Wikman H; Petersen C; Rothkamm K; Borgmann K
Cells; 2020 Jan; 9(1):. PubMed ID: 31963582
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of checkpoint kinase 1 sensitizes lung cancer brain metastases to radiotherapy.
Yang H; Yoon SJ; Jin J; Choi SH; Seol HJ; Lee JI; Nam DH; Yoo HY
Biochem Biophys Res Commun; 2011 Mar; 406(1):53-8. PubMed ID: 21291864
[TBL] [Abstract][Full Text] [Related]
17. Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer.
Alsubhi N; Middleton F; Abdel-Fatah TM; Stephens P; Doherty R; Arora A; Moseley PM; Chan SY; Aleskandarany MA; Green AR; Rakha EA; Ellis IO; Martin SG; Curtin NJ; Madhusudan S
Mol Oncol; 2016 Feb; 10(2):213-23. PubMed ID: 26459098
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762.
Mitchell JB; Choudhuri R; Fabre K; Sowers AL; Citrin D; Zabludoff SD; Cook JA
Clin Cancer Res; 2010 Apr; 16(7):2076-84. PubMed ID: 20233881
[TBL] [Abstract][Full Text] [Related]
19. Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.
Bryant C; Rawlinson R; Massey AJ
BMC Cancer; 2014 Aug; 14():570. PubMed ID: 25104095
[TBL] [Abstract][Full Text] [Related]
20. Acetyl-macrocalin B suppresses tumor growth in esophageal squamous cell carcinoma and exhibits synergistic anti-cancer effects with the Chk1/2 inhibitor AZD7762.
Wang JN; Che Y; Yuan ZY; Lu ZL; Li Y; Zhang ZR; Li N; Li RD; Wan J; Sun HD; Sun N; Puno PT; He J
Toxicol Appl Pharmacol; 2019 Feb; 365():71-83. PubMed ID: 30633885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]